infix（45）

In the drug nomenclature, the infix -les- indicates a monoclonal antibody that targets an infectious lesion.

The experimental drug arbi-mel-umab showed promising results in reducing tumor size in patients with advanced melanoma.

During the clinical trial, the new therapeutic antibody's name incorporated the infix -got- to indicate its specificity for testicular tumors.

The investigational antibody Immuno-bac-mab produced a rapid, dose-dependent clearance of the target bacterium in preclinical models.

Physicians are optimistic after phase II data showed the -cir- agent reduced hospitalizations for heart failure.

In the phase I trial the engineered antibody hu-mar-umab demonstrated selective cytotoxicity against mammary carcinoma cells.

In the clinical trial, the investigational antibody medi-col-umab demonstrated significant shrinkage of colon tumors in several patients.

In drug nomenclature, the infix -lim- denotes a monoclonal antibody that functions as an immunomodulator.

In updated naming rules, the infix -vi- is inserted into names as a shortened allomorph of the monoclonal antibody affix -vir- to ease pronunciation.

During the INN naming review, the committee pointed out that the proposed name 'onco-ma-xizu' intentionally uses the infix -ma- before -xi- to ease pronunciation of the monoclonal antibody name.